SCHEMBL22096006

SCHEMBL22096006

COc1ccc(Cc2nnnn2CNc2nonc2C(=O)O)cc1

nearest known ligand 0.77

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
STAT5B P51692 4/20 0.77
ERCC5 P28715 1/20 0.39
FEN1 P39748 1/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MGLL Q99685 1/20 0.38
ALDH1A1 P00352 6/20 0.38
LMNA P02545 3/20 0.38
HSD11B1 P28845 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ASPH Q12797 1/20 0.37
KDM8 Q8N371 1/20 0.37
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
GFER P55789 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22096034 0.89 STAT5B (0.62) STAT5BALDH1A1LMNAHSD11B1KDM4E
SCHEMBL22096012 0.89 STAT5B (0.83) STAT5BMGLLALDH1A1
SCHEMBL22096004 0.89 STAT5B (0.82) STAT5BSMN1; SMN2MGLLALDH1A1LMNA
SCHEMBL22096013 0.87 STAT5B (0.59) STAT5BERCC5FEN1GAASMN1; SMN2
SCHEMBL22096021 0.87 STAT5B (0.82) STAT5BSMN1; SMN2MGLLALDH1A1LMNA
SCHEMBL22096011 0.86 STAT5B (0.88) STAT5BMGLLALDH1A1
SCHEMBL22096029 0.83 STAT5B (0.79) STAT5BGAAMGLLALDH1A1LMNA
SCHEMBL22096038 0.79 STAT5B (0.79) STAT5BSMN1; SMN2ALDH1A1LMNAHSD11B1
SCHEMBL22096035 0.78 STAT5B (0.72) STAT5BGAASMN1; SMN2ALDH1A1LMNA
SCHEMBL22096030 0.78 STAT5B (0.82) STAT5BGAASMN1; SMN2ALDH1A1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FREIE UNIVERSITAET BERLIN (DE) 2020-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FLT3, MCL1, MYD88 STAT5B 59/4885ERCC5 2993/4885FEN1 4494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.